American College of Cardiology Expands Patient Navigator Program
Patient-Centered Program to Focus on Reducing MI Readmissions Nationally
Contact: Nicole Napoli, firstname.lastname@example.org, 202-375-6523
WASHINGTON (Feb 08, 2018) -
Hundreds of hospitals across the United States will have access to tools and resources to help improve care and lower readmission rates for myocardial infarction (MI) patients as part of the American College of Cardiology’s expanded Patient Navigator Program: Focus MI Quality Campaign.
With support from founding sponsor AstraZeneca, the expanded program will provide hospitals participating in the ACC’s ACTION Registry the opportunity to transform care by sharing successful strategies, mentorship and specialized tools and resources. In addition, 15 of the original 35 hospitals from the first phase of the Patient Navigator Program will focus on identifying best practices for improving patient care and readmissions, including 30 and 90 days follow up post hospital discharge – an increasing area of focus for proposed payment and reimbursement models.
“Since the original Patient Navigator Program launched, hospitals and cardiovascular care team members have led the way in developing effective ways to help manage patients’ heart health after they leave the hospital,” said ACC President Mary Norine Walsh, MD, FACC. “The Patient Navigator Program: Focus MI aims to build on what we have learned to help hospitals across the country reduce readmission rates while improving patients’ long-term outcomes.”
A total of 35 U.S. hospitals participated in the initial Patient Navigator Program, which launched in 2013 and focused on reducing 30-day hospital readmissions for MI and heart failure patients. Hospitals participating in the program reported increases in the number of MI patients assessed for risk of readmissions and greater understanding among MI and heart failure patients about their medications. In addition, they were able to reach both groups of patients with education and community resources aimed at ensuring smoother patient transitions from hospital to home. Results will be presented in greater detail at ACC’s 67th Annual Scientific Session in Orlando, from March 10-12.
“The progress from the ACC Patient Navigator Program has provided great evidence into the importance of putting programs in place to address transition of care for patients following a heart attack,” said Rod Wooten, Vice President, CVMD, AstraZeneca. “As hospitals continue to seek evidence-based strategies to improve quality of care, our hope is that providing continued support to the Patient Navigator Program: Focus MI will address the important topic of reducing MI readmissions for patients nationally.”
Hospitals that enroll in the Patient Navigator Program: Focus MI access evidence based toolkits, self-assessment tools, a learning community of national experts and peer colleagues, and an ACTION Registry dashboard specifically designed to track Patient Navigator Program: Focus MI metrics. The select 15 Diplomat Hospitals, focus on reducing 90-day readmissions for MI patients and provide mentorship for wider adoption of the program across other institutions.
The American College of Cardiology is the professional home for the entire cardiovascular care team. The mission of the College and its more than 52,000 members is to transform cardiovascular care and to improve heart health. The ACC leads in the formation of health policy, standards and guidelines. The College operates national registries to measure and improve care, offers cardiovascular accreditation to hospitals and institutions, provides professional medical education, disseminates cardiovascular research and bestows credentials upon cardiovascular specialists who meet stringent qualifications. For more, visit acc.org.
AstraZeneca is a global, science-led biopharmaceutical company that focuses on the discovery, development and commercialization of prescription medicines, primarily for the treatment of diseases in three therapy areas – Oncology, Cardiovascular & Metabolic Diseases and Respiratory. The Company also is selectively active in the areas of autoimmunity, neuroscience and infection. AstraZeneca operates in over 100 countries and its innovative medicines are used by millions of patients worldwide. For more information, please visit www.astrazeneca-us.com and follow us on Twitter @AstraZenecaUS.